HemoCath
HemoCath AI-powered heart failure management platform — Reducing HF hospitalizations & hospital stay
- Stage Full Product Ready
- Industry Medical Devices and Equipment
- Location Lisle, IL, USA
- Currency USD
- Founded June 2020
- Employees 6
- Incorporation Type C-corp
- Website hemocath.com
Company Summary
HemoCath is a US/Irish pre-revenue company that has developed and is now commercializing the HemoCath™ pulmonary artery (PA) catheter and the Luc™ heart failure management (HFM) platform — improving HF management — reducing HF hospitalizations & hospital stay — providing hospital costs savings.
Raising $500k Bridge round to support due diligence by large VCs and prepare for US market entry (in convertible notes, 20% discount, $10M cap)
Team
-
President & CEOMedtech Entrepreneur and Growth Leader with an excellent track record of innovative product development supported with strong IP, commercialization, sales and team building. Over 25 years as a Medtech/Hardtech entrepreneur from concept to commercialization, technology assessment, identification and evaluation of unmet medical/market needs. Inventor on 21 patents. Graduated with a BS in electrical/software engineering and MBA.
-
CTODes is an expert in engineering development of novel medical devices, with an impressive track record over the past 30 years. He founded and lead a number of startup companies developing medical devices in Ireland. Des has been Director of Product Development in established companies such as Nordson Medical, Phillips Medisize and Medtronic. Inventor on 23 patents in the medical field. He holds a BS and MS in mechanical engineering.
-
CROMichael Nagy, MSEE Case Western Reserve, has led advanced engineering teams for 33 years at a series of successful start-ups. He has transformed breakthrough microsensor, microelectronics, and micro-optics technologies into products for a variety of industries. In 2008 he co-founded Endotronix and led development of its wireless implantable sensor system from inception through current PMA trials. Inventor on 27 US patents.
-
Christopher Glover, MD, FRCPCCMODr. Christopher Glover is Interventional Cardiologist and Director of Cardiac Catheterization at the University of Ottawa Heart Institute. Dr. Glover is also Associate Professor and Director of Education and Clinical Services in the division of cardiology at the University of Ottawa. His expertise in valve diseases and transcatheter valve replacements was achieved overtime through 20+ years as an interventional cardiologist.
-
CFO & Member Board of DirectorsSeasoned corporate development strategist with 30+ years of executive and public practice experience. Chartered Professional Accountant, Chartered Business Valuators and senior member of American Society of Appraiser with a speciality in business valuation. Currently, co-founder & CEO of Life360 Innovations, commercializing a medical device for men with urinary incontinence. In addition, a board member and advisor for a number of companies.
Advisors
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.